Bubae
1 day ago
I see a 72% gross on $42,526 in sales down from the same period 2023 of $323,613. Sales down as a result of product line change. Like I showed in my previous post net loss of $724,643 for the three months ended September 30, 2024, compared to a net loss of $376,720 for the three months ended September 30, 2023. The stock is clinging to $0.0002 for a reason and I'm betting you will have the opportunity to buy as many of those as you can handle for quite a while longer.
Bubae
1 day ago
Yeah, they do have the deposits for future sales but their net loss year over year for the quarter nearly doubled. They struggle with debt in default and the Mast Hill activity dumping at an apparent loss is not a good look. That activity doesn't account for the more than 500 million shares dumped since mid December and I'm not motivated to dig down to see where the additional dilution is coming from. I would just assume that the unknown source of dilution may continue and question why Mast Hill is taking a significant hit on those $0.0005 conversions rather than hold. I assume that Mast Hill is seeing something that I don't. Just trying to read between the lines here but it is a stinky pink after all.
For the quarterly period ended September 30, 2024.
https://www.otcmarkets.com/filing/html?id=17988091&guid=FK0-ke5LYXZIB3h
Page 14
As of September 30, 2024, and separately, the Company is in default of a matured convertible promissory note, issued to a lender on August 8, 2022, with principal and interest due in the amounts of $93,000 and $51,099, respectively. The convertible note included a cross-default and a cross-default provision which required the Company to remit payment of principal, accrued interest, default interest, and legal fees, multiplied by 150%. The amount of approximately $72,000 in default penalties has been accrued and is recorded in the Company’s balance sheet as of September 30, 2024 for this lender. The Company is in negotiations with the lender to reform the note in default.
Excerpts form page 19 and 20
Operating Results
July 1, 2024 through September 30, 2024 Compared to July 1, 2023 through September 30, 2023
Our sales totaled $42,526 for the three months ended September 30, 2024 and $323,613 for the three months ended September 30, 2023, a decrease of $281,087 or 87%. The decrease is primarily related to a decrease in units sold. Unit sales have decreased as the Company winds down the sale of its current product leading up to the introduction of the new Wellness Pro Infinity. In June 2024, the Company initiated its exchange program, allowing current customers to submit deposits for the new Wellness Pro Infinity. Deposits totaling $764,125 have been collected as of September 30, 2024 for the new product.
As a result of the foregoing, we recorded a net loss of $724,643 for the three months ended September 30, 2024, compared to a net loss of $376,720 for the three months ended September 30, 2023. The decrease in net loss is primarily attributed to the increased loss from operations and the increase in other expense.
Bubae
1 day ago
Not looking good for this if you consider the series of twelve debt conversions by Mast Hill Fund. The first of the 506 reg D restricted conversions was on March 26, 2024 with a conversion price of $0.001. By the time that conversion vested at the end of September the stock would be trading at $0.0005. The next conversion for Mast Hill was April 29 the the same terms priced at $0.001. Again, by the time the restricted conversion vested at the end of October the best they could do was $0.0005. From there we look at the balance of the twelve conversions done, apply a little math, compare the current restricted outstanding share count and we can see that the shares are being sold on a regular basis when vested. After the April conversion the rest are done at $0.0005 up to November 01, 2024. Looking at the chart for the past few months we can see that those shares would have had to be sold at a loss.
I found a post by Chartmaster stating that the Unrestricted OS was only 811,256,652 on December 12, 2024. Consider the current unrestricted OS is 1,328,145,692 we find that 516,889,040 had been added since the December post. This is far more than can be accounted for by the Mast Hill conversions. The current Mast Hill restricted conversions should play out until the beginning of May when the November 01, 2024 conversions vest. If the company's prospects going forward were good why is Mast Hill dumping these conversions at a loss. Link to the Q3 below. Did Mast Hill wait until the first two conversions vest before dumping them? I see a couple of nice run-ups that would have been advantageous. One in May and the other in August with both having a steep sell-off afterwards. The list of Mast Hill conversions begins on page 41 of the Q3 2024 filing.
For the quarterly period ended September 30, 2024.
https://www.otcmarkets.com/filing/html?id=17988091&guid=FK0-ke5LYXZIB3h
Chartmaster
Re: None
Thursday, December 12, 2024 10:00:09 AM
Post# 3619 of 3658
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175517424
Unrestricted OS only 811,256,652 12/11/2024
https://www.otcmarkets.com/stock/EMED/security
Viewmont
2 months ago
$EMED $$$ Electromedical Technologies Unveils Groundbreaking Details About the WellnessPro Infinity and Announces Production Timeline
Electromedical Technologies is excited to share key updates on the WellnessPro Infinity, a revolutionary device redefining the standards of pain management and wellness technology.
SCOTTSDALE, ARIZONA / ACCESSWIRE / December 11, 2024 / Electromedical Technologies, Inc. (OTC PINK:EMED) - Electromedical Technologies is excited to share key updates on the WellnessPro Infinity, a revolutionary device redefining the standards of pain management and wellness technology. With production set to ramp up in early 2025, the WellnessPro Infinity is poised to deliver unparalleled precision and performance, setting a new benchmark in its class.
A Journey of Innovation
At the heart of the WellnessPro Infinity is an unprecedented design that incorporates 11 intricately engineered circuit boards covering nearly one-square-foot and 1,454 individual components, all housed within a sleek looking device.
Each circuit board serves a specific function, working in perfect synchronization to ensure precision and efficiency. These boards include cutting-edge:
Microcontrollers: Advanced processors regulate input and output signals, ensuring reliable and consistent operation. These components are highly sought after in industries like automotive and military for their durability and precision.
Precision Resistors and Capacitors: These components ensure signal accuracy and stability, providing the consistent therapeutic effects the WellnessPro Infinity is known for.
Signal Amplifiers: Amplify low-level electrical signals to deliver varying intensities for customized treatment.
Power Management Systems: Ensure optimal energy usage, protect the device from surges, and extend the device's operational lifespan.
User Interface Modules: Enable intuitive control, allowing users to customize treatment settings with ease.
This intricate assembly highlights the company's dedication to innovation, bringing together advanced engineering and cutting-edge technology to create a device that stands apart in the marketplace.
Overcoming Challenges Together
The road to production has been both complex and rewarding. Global supply chain disruptions and rigorous European manufacturing standards posed significant challenges. Additionally, sourcing high-demand components, such as microcontrollers often reserved for critical industries like military and automotive, added to the production intricacy.
"We deeply appreciate the patience of our customers and partners as we've worked to overcome these challenges," said Matthew Wolfson, Chief Executive Officer of Electromedical Technologies. "The WellnessPro Infinity will deliver on its promise to revolutionize pain management, making it well worth the wait."
Looking Ahead
Production is scheduled to ramp up in the third week of 2025, with rigorous factory evaluations underway to ensure all processes meet the company's high standards. Electromedical Technologies will provide detailed shipping timelines once evaluations are complete.
For customers who pre-ordered the device, Electromedical Technologies reaffirms its commitment to honor all pre-sale pricing, even as market prices are set to adjust in 2025.
Thank You for Believing in Us
The WellnessPro Infinity is not just a device-it's a testament to innovation, resilience, and a shared vision for improving lives through technology.
"By choosing the WellnessPro Infinity, you've joined us on a journey to bring cutting-edge technology to life," Mr. Wolfson added. "We're grateful for your belief in this revolutionary product and excited about the transformative impact it will have."
About Electromedical Technologies
Electromedical Technologies is a leader in the development of bioelectronic devices that improve health and wellness. Dedicated to innovation and excellence, the company's flagship products provide effective pain relief and enhance quality of life through advanced technology.
For more information, visit www.electromedtech.com.
Corporate Contact:
Electromedical Technologies, Inc. Tel: 1.888.880.7888
Email: ir@electromedtech.com
https://electromedtech.com
Contact Information
Cristina Clubb
Electromedical Technologies, Inc.
ir@electromedtech.com
https://stats.nwe.io/x/im?ref=WyI0bzZqdHYiXQ&hit%2Csum=WyI0ZXBobnkiLCI0ZW05bW4iLCI0bzZqdHYiLCI0bzZqdHciXQ
SOURCE: Electromedical Technologies, Inc.